Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:

• Introduction (0:00)
• Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24)
• Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10)
• Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54)
• Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00)
• Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33)
• Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05)
• FL and Other NHL Subtypes — Dr Sehn (45:30)

CME information and select publications

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:

• Introduction (0:00)
• Best of ASH Multiple Myeloma (1:56)
• Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35)
• Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58)
• Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57)
• Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42)
• Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09)
• Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07)
• Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44)

CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics:

• Introduction (0:00)
• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39)
• Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52)
• Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy — Laila Agrawal, MD (20:02)
• Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (25:10)
• Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer — Zanetta S Lamar, MD (35:03)
• Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin (46:20)
• Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy — Justin Favaro, MD, PhD (59:41)
• Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis — Dr Agrawal (1:05:36)
• Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop (1:12:00)
• Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression — Yanjun Ma, MD, PhD (1:23:04)
• Tolerability Considerations with HER2-Targeted Therapies — Dr O'Shaughnessy (1:29:32)
• Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma — Erik Rupard, MD (1:46:06)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging — Kimberly Ku, MD
  Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease — Richard Zelkowitz, MD (1:49:49)

CME information and select publications

Featuring perspectives from Dr Nancy L Bartlett, Dr John P Leonard, Dr Matthew Matasar, Dr Loretta J Nastoupil and Prof Pier Luigi Zinzani, including the following topics:

• Introduction (0:00)
• Rational Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Matasar (1:34)
• Case: A man in his late 50s who presents with left testicular swelling and abdominal discomfort is diagnosed with ABC-subtype Stage IV DLBCL — Laurie H Sehn, MD, MPH (11:27)
• Clinical Utility of CD19-Directed Monoclonal Antibodies for DLBCL and Follicular Lymphoma (FL) — Dr Leonard (19:00)
• Case: A woman in her early 80s with refractory DLBCL receives tafasitamab/lenalidomide — Carla Casulo, MD (32:50)
• Case: A man in his late 70s with chronic renal disease and relapsed cutaneous DLBCL receives tafasitamab and dose-reduced lenalidomide — Matthew Lunning, DO (35:51)
• Optimal Use of ADCs in the Treatment of Relapsed/Refractory DLBCL — Prof Zinzani (42:09)
• Case: A woman in her late 60s with relapsed DLBCL after polatuzumab vedotin with bendamustine/rituximab receives loncastuximab tesirine with partial response and develops a rash — Dr Casulo (57:45)
• Case: A woman in her early 40s with multiregimen-relapsed GCB-type DLBCL experiences disease progression on loncastuximab tesirine and receives brentuximab vedotin with lenalidomide/rituximab (1:03:07)
• Bispecific Antibody Therapy for DLBCL — Dr Bartlett (1:08:31)
• Case: A man in his mid 60s with DLBCL and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (1:22:33)
• Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and COPD receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Dr Lunning (1:29:06)
• Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes — Dr Nastoupil (1:35:34)
• Case: A woman in her mid 50s with multiregimen-recurrent FL receives mosunetuzumab — Dr Casulo (1:47:01)
• Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab and achieves an ongoing complete response — Dr Sehn (1:52:23)

CME information and select publications

Featuring an interview with Dr Scott Kopetz, including the following topics:

• Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00)
• Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01)
• Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a methylation-based, tissue-free ctDNA test (12:51)
• ctDNA with locally advanced mismatch repair-deficient/microsatellite instability-high solid tumors; real-world evidence regarding ctDNA with resected CRC (17:31)

CME information and select publications

Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics:

• Introduction (0:00)
• Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46)
• Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09)
• Discussion: Asymptomatic MF; re-reads of pathology reports; "triple-negative" MF; secondary causes — Laura C Michaelis, MD (22:47)
• Discussion: Ruxolitinib-associated dermatologic cancers and weight gain — Prithviraj Bose, MD (27:34)
• Managing MF in Patients with Anemia — Dr Oh (30:21)
• Case: A man in his early 70s with splenomegaly and mild fatigue is diagnosed with JAK2 V617F-mutant primary MF and receives momelotinib — Dr Michaelis (42:34)
• Discussion: Post-hoc analysis from the SIMPLIFY-1 trial — Dr Bose (46:20)
• Managing MF in Patients with Thrombocytopenia — Dr Rampal (49:57)
• Discussion: MF with moderate thrombocytopenia — Dr Michaelis
  Case: A man in his mid 60s with primary MF and anemia, thrombocytopenia and splenomegaly has a low JAK2 V617F allele frequency — Dr Mascarenhas (1:05:46)
• Promising Novel Agents Under Investigation for MF — Prof Harrison (1:11:21)
• Case: A woman in her late 70s with primary MF with CALR1 and SF3B1 mutations and anemia receives luspatercept — Dr Michaelis
  Discussion: Luspatercept for MF-associated anemia — Dr Bose (1:24:52)
• Discussion: Promising novel therapies — Dr Mascarenhas (1:28:24)
• Current and Future Management of Systemic Mastocytosis — Dr Kuykendall (1:32:40)
• Discussion: Initial assessment of patients diagnosed with systemic mastocytosis; avapritinib dosing — Dr Bose (1:49:12)
• Discussion: Systemic mastocytosis with associated hematologic neoplasm — Dr Bose (1:52:24)
• Discussion: Bezuclastinib for systemic mastocytosis — Dr Bose (1:55:23)

CME information and select publications

Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics:

• Introduction (0:00)
• Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50)
• Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued — Alan Astrow, MD (6:47)
• Previously Untreated Metastatic TNBC (mTNBC) — Prof Schmid (10:47)
• Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan — Jennifer Yannucci, MD (27:19)
• Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) — Ranju Gupta, MD; Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol — Yanjun Ma, MD, PhD (31:35)
• Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Sharma (36:31)
• Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission — Dr Gupta; Case: Management of neutropenia associated with sacituzumab govitecan — Gigi Chen, MD (50:30)
• Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease — Dr Gupta; Case: Management of T-DXd-related side effects — Laila Agrawal, MD (54:10)
• Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC — Dr Nanda (58:59)
• Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd — Atif M Hussein, MD, MMM (1:12:40)
• Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés (1:18:10)

CME information and select publications

Featuring perspectives from Dr Matthew S Davids, Dr Bita Fakhri, Prof Constantine Tam and Dr Jennifer Woyach, including the following topics:

• Introduction (0:00)
• Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids (1:42)
• Case: A man in his mid 70s with a plethora of comorbidities but good performance status requires treatment for CLL — Bhavana (Tina) Bhatnagar, DO (14:58)
• Case: A man in his early 50s, a Jehovah's Witness, under observation for IGHV-mutated CLL develops pulmonary emboli and worsening lymphadenopathy, undergoes anticoagulation and begins therapy with zanubrutinib — Jennifer Yannucci, MD
• Case: A man in his mid 70s with a history of atrial fibrillation on apixaban receives zanubrutinib — Zanetta S Lamar, MD (22:30)
• Optimal Management of Adverse Events with Bruton Tyrosine Kinase and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Prof Tam (32:50)
• Case: A man in his mid 90s with CLL has concurrent locally advanced Merkel cell carcinoma of the scalp — Erik Rupard, MD (50:51)
• Case: A woman in her early 50s under observation for IGHV-unmutated CLL develops progressive splenomegaly and receives obinutuzumab/venetoclax — Sean Warsch, MD (54:28)
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Woyach (1:05:51)
• Case: A man in his mid 70s with high-risk (del[TP53]) CLL experiences disease progression on ibrutinib and then venetoclax/obinutuzumab — Dr Bhatnagar (1:27:23)
• Case: A man in his early 80s with IGHV-unmutated CLL who previously received FCR now experiences disease relapse after 5 years of acalabrutinib, and a BTK C481S resistance mutation is detected — Priya Rudolph, MD, PhD (1:29:34)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Fakhri (1:34:08)
• Case: A man in his early 70s with multiregimen-relapsed CLL experiences an 18-month response to pirtobrutinib — Brian P Mulherin, MD (1:50:46)

CME information and select publications